Back

Phase I gene therapy clinical trial design of RP-A601 in adult patients with PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM)

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiovascular trends: hospitalisations, trials, and genetic therapies Trial Design ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Matthew Coggins

(United States of America)

3 More presentations in this session

Presentation thumbnail
Reassessing pharmacological trials with positive composite outcome driven by reduction in nonfatal myocardial infarction: a systematic review and meta-analysis
Mr H. Sun (CN)
Abstract Slides Video
Presentation thumbnail
Association between autonomic dysfunction, 12-year mortality and 10-year incident cardiovascular disease
Doctor B. Hernandez (Dublin, IE)
Abstract Slides Video
Presentation thumbnail
First trimester maternal infections and offspring congenital heart defects: a systematic review and meta-analysis
Miss H. Su (Leuven, BE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular trends: hospitalisations, trials, and genetic therapies
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Real-world evaluation of an algorithmic machine-learning-guided testing approach in stable chest pain: a multinational, multicohort study
thumbnail
Congress Session
How to implement a successful telemedicine program in heart failure
thumbnail
Congress Presentation
AI-based drug design and AI-based clinical trials - discussion

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources